Gly-β-MCA may be a candidate for the treatment of metabolic disorders. Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive f...
||(-)-PX20606 trans isomer
(-)-PX20606 trans isomer is an agonist of FXR (EC50s: 18 and 29 nM for FXR in FRET and M1H assay, respectively). |
||Tauro-β-muricholic acid sodium
Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM). |
LY367385 is a highly effective and selective mGluR1a antagonist. LY367385 has neuroprotective, anticonvulsant, and antiepileptic effects. Compared with > 100 μ...
Obeticholic acid is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist. |
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity compared to natural compounds. |
Lithocholic acid is a bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubil...
GW 4064 is an effective farnesoid X receptor (FXR) agonist (EC50 =65 nM). |
Hyodeoxycholic Acid has been used in trials studying the treatment of Hypercholesterolemia. |
Tropifexor is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM. |
Androsterone is a metabolic product of testosterone and can activate Farnesoid X Receptor (FXR). |
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM |
T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB). |
Cilofexor inhibits binding of a synthetic peptide, Cilofexor is a farnesoid X receptor (FXR) agonist. |
Nidufexor is a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. |
Vonafexor is a farnesoid X receptor (FXR, NR1H4) agonist, with anti-HBV effects |
Nelumol A, and nelumal A show a potency comparable to the endogenous ligand, they may as a valuable potential novel lead compound in the search for FXR agonists...
BAR502 is a dual GPBAR1 and FXR agonist (IC50s: 0.4 μM and 2 μM). |